Positive VOLGA Phase III Results for Imfinzi Plus Neoadjuvant EV in MIBC
oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]
AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.
- Clinician reactions, biology and resistance concerns (4)
- Global GU oncology meetings and community coverage (3)
- VOLGA Phase III readout and regulatory landscape (3)
- All Other Stories
Clinician reactions, biology and resistance concerns
Global GU oncology meetings and community coverage
VOLGA Phase III readout and regulatory landscape
All Other Stories
Related Stories
FDA greenlights datopotamab deruxtecan for metastatic TNBC / 14 days
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 21 days
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 5 wks
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 14 days
Datroway secures regulatory approvals in breast cancer across US and EU / 7 wks
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 1 month
FDA grants early access to experimental pancreatic cancer drug / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supplements, Eli Lilly, Trump Administration, Drug Development and look for the RSS link.
StackHealth Time Machine